Rift Valley fever (RVF) in Zambia was first reported in 1974 during an epizootic of cattle and sheep that occurred in parts of Central, Southern and Copperbelt Provinces. In 1990, the disease was documented in nine districts of the provinces of Zambia. In the last two decades, there have been no reports of RVF. This long period without reported clinical disease raises questions as to whether RVF is a current or just a perceived threat. To address this question, World Organisation for Animal Health (OIE) disease occurrence data on RVF for the period 2005-2010 in the Southern Africa Development Community (SADC) was analysed. From the analysis, it was evident that most countries that share a common border with Zambia had reported at least one occurrence of the disease during the period under review. Due to the absence of natural physical barriers between Zambia and most of her neighbours, informal livestock trade and movements is a ubiquitous reality. Analysis of the rainfall patterns also showed that Zambia received rains sufficient to support a mosquito population large enough for high risk of RVF transmission. The evidence of disease occurrence in nearby countries coupled with animal movement, and environmental risk suggests that RVF is a serious threat to Zambia. In conclusion, the current occurrence of RVF in Zambia is unclear, but there are sufficient indications that the magnitude of the circulating infection is such that capacity building in disease surveillance and courses on recognition of the disease for field staff is recommended. Given the zoonotic potential of RVF, these measures are also a prerequisite for accurate assessment of the disease burden in humans.

Corneal injury is very common clinical condition in veterinary medicine and delayed or incomplete corneal healing has the potential of vision loss due to the loss of corneal transparency. For the reconstruction of corneal epithelium, tissue graft and cell transplantation have been prosperously investigated. The purpose of this study was to evaluate the clinical value and short-term safety of application of cultured allogenic mesenchymal stem cells (MSCs) in the treatment of canine experimental corneal defect. Corneal defects were surgically generated in the central corneas of healthy beagle dogs and cultured canine allogenic MSCs were transplanted via subconjunctival injection. Although mean healing time, the rate of epithelial regeneration, and the degree of corneal transparency were not significantly improved after MSC transplantation, significant immune reaction or incompatibility reaction was not detected except transient local irritation. These results propose the possibility of MSC application as a new regenerative medicine in canine ocular disorders.